ARTICLE SUMMARY:
Aortica has developed a simple, fast, and cost-effective way to create patient-specific fenestrated endografts for complex abdominal aortic aneurysms, and it believes the technology has the potential to reignite growth in the EVAR market.
Growth in the $1.5 billion global endovascular abdominal aortic aneurysm repair (EVAR) market has slowed to the low-to-mid single digits in recent years, as competitive pressures weighed on standard endograft pricing and manufacturers labored to develop new technologies capable of expanding EVAR to more complex cases.
